Lipocine Announces Financial and Operational Results for the Full Year 2014
March 11, 2015 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, March 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well...
Lipocine to Present at the 27th Annual ROTH Conference
March 04, 2015 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015
February 27, 2015 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement...
Lipocine to Present at the Cowen and Company 35th Annual Health Care Conference
February 24, 2015 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and Chief Executive Officer, and...
Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting
January 30, 2015 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's...
Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women
January 12, 2015 09:00 ET
|
Lipocine Inc.
First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women
Projected dose between 400 and 800 mg twice a day is expected to be...
FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021
December 15, 2014 08:30 ET
|
Lipocine Inc.
SALT LAKE CITY, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug...
Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
November 25, 2014 08:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
Lipocine Announces Management Changes
November 17, 2014 08:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the...
Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
November 10, 2014 08:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well...